DrSuePedersen (@drsuepedersen) 's Twitter Profile
DrSuePedersen

@drsuepedersen

ID: 46334472

linkhttp://www.drsue.ca calendar_today11-06-2009 06:55:29

2,2K Tweet

1,1K Followers

137 Following

DrSuePedersen (@drsuepedersen) 's Twitter Profile Photo

drsue.ca/2025/03/could-… Some men with elevated weight struggle with infertility. Given the weight and metabolic benefits of GLP1 receptor agonists, could liraglutide #Saxenda, semaglutide #Wegovy, or tirzepatide #Mounjaro #Zepbound improve male reproductive health?

DrSuePedersen (@drsuepedersen) 's Twitter Profile Photo

Excited to be faculty on this med ed sesh on GLP1-based combination therapies for obesity, with my friends and colleauges Drs Donna Ryan and Carel Le Roux touchendocrinologyime.org/novel-combinat…

DrSuePedersen (@drsuepedersen) 's Twitter Profile Photo

drsue.ca/2025/03/when-y… When taking weight management medication, what other medications taken for other health issues may need adjusting?

DrSuePedersen (@drsuepedersen) 's Twitter Profile Photo

drsue.ca/2025/03/could-… While we know that hormones and genetics play a big role in the physiology of hunger, there are around a trillion other reasons that are getting more credit for their contributions these days - learn about these microcritters here!

DrSuePedersen (@drsuepedersen) 's Twitter Profile Photo

Could higher smartwatch-recorded average heart rate per step taken per day be associated with higher risk of diabetes, high BP, CV disease, heart failure? This study suggests yes. medscape.com/viewarticle/ne…

DrSuePedersen (@drsuepedersen) 's Twitter Profile Photo

Diazoxide-choline ER (Vykat XR) approved by FDA as first treatment for hyperphagia in Prader Willi syndrome investors.soleno.life/news-releases/…

DrSuePedersen (@drsuepedersen) 's Twitter Profile Photo

drsue.ca/2025/04/first-… I'm honored to have been an investigator in the SOUL study, the first GLP-1 in a pill to reduce cardiovascular events in people with type 2 diabetes!

DrSuePedersen (@drsuepedersen) 's Twitter Profile Photo

drsue.ca/2025/04/the-hi… While heart attack and stroke risk are top of mind for clinicians, peripheral artery disease is often overlooked. What are the symptoms, how is it diagnosed, and what can we do about it?

DrSuePedersen (@drsuepedersen) 's Twitter Profile Photo

First phase 3 study of small molecule (non peptide) GLP1 in a pill - orforglipron - topline results show a1c lowering up to 1.6%, and up to 7.9% weight loss. Looking forward to the publication and presentation at this year's ADA meeting! investor.lilly.com/news-releases/…

DrSuePedersen (@drsuepedersen) 's Twitter Profile Photo

drsue.ca/2025/04/can-we… For a person living with #obesity who has had already had a hip or knee replaced, can #weightloss with obesity medication reduce the risk of needing a revisional surgery?

DrSuePedersen (@drsuepedersen) 's Twitter Profile Photo

drsue.ca/2025/05/zepbou… Tirzepatide, which has been approved in Canada as a diabetes medication (#Mounjaro) since 2022, received Health Canada approval for weight management this week (called #Zepbound). What do you need to know?

DrSuePedersen (@drsuepedersen) 's Twitter Profile Photo

drsue.ca/2025/06/mazdut… Could GLP1 and glucagon work together to provide weight loss benefits and improvements to metabolic and liver health? Find out about the results of the first phase 3 study of a dual GLP1/glucagon receptor agonist (mazdutide) here!

DrSuePedersen (@drsuepedersen) 's Twitter Profile Photo

healio.com/news/endocrino… Excited to have the opportunity to speak the Counter argument on the Lancet Commission diagnosis of #obesity!

DrSuePedersen (@drsuepedersen) 's Twitter Profile Photo

drsue.ca/2025/06/could-… Diabetes is a risk factor for cardiovascular (CV) disease. But could the risk of heart attack and stroke be elevated, even DECADES before the diagnosis of type 2 #diabetes is made? Find out more here!

DrSuePedersen (@drsuepedersen) 's Twitter Profile Photo

drsue.ca/2025/06/wegovy… I was honored to present the REDEFINE 1 and REDEFINE 2 trial results of CagriSema with colleagues at a symposium today at the American Diabetes Association (ADA) meeting. Find out the results here!